Skip to main content
Clinical Trials/NCT06417281
NCT06417281CompletedPhase 3

A Phase III Clinical Trial of Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.1 site in 1 country86 target enrollmentStarted: June 19, 2024Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 3
Status
Completed
Enrollment
86
Locations
1
Primary Endpoint
positive predictive rate of tissue fluorescence per biopsy sample taken from fluorescent sites

Study Overview

Brief Summary

This trial is an open-label, multicenter, phase III clinical study,conducted in patients with newly diagnosed or recurrent malignant high-grade (WHO grades 3~4) glioma, to evaluate the efficacy and safety of a single oral dose of 5-aminolevulinic acid (5-ALA) oral solution powder for fluorescence-guided tumor resection and photodynamic diagnosis.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patient's written informed consent
  • Age 18-75 years
  • Radiological suspicion of a malignant glioma
  • Indication for surgical tumour resection
  • Karnofsky Performance Status (KPS) ≥ 70

Exclusion Criteria

  • Tumor located in the basal ganglia, thalamus, cerebellum, or brainstem
  • Porphyria, hypersensitivity to porphyrins,history of cutaneous photosensitivity or photosensitive skin diseases;
  • known hypersensitivity to the test drug ingredients
  • Any other condition that, in the opinion of the investigator, makes participation in the trial inappropriate;

Arms & Interventions

5 Aminolevulinic Acid

Experimental

This is an single arm study.

Intervention: 5 Aminolevulinic Acid (Drug)

Outcomes

Primary Outcomes

positive predictive rate of tissue fluorescence per biopsy sample taken from fluorescent sites

Time Frame: within 48 hours after surgery

The proportion of biopsy tissues diagnosed as malignant glioma cells positive by pathological examination among all tissues collected from both fluorescent and weakly fluorescent areas.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials